The global opioid induced constipation treatment market is highly consolidated with the presence of few companies. The top three companies, namely Takeda Pharmaceutical Company Ltd, Valeant Pharmaceuticals International Ltd, and Boehringer Ingelheim, dominate the global opioid induced constipation treatment market.
These three companies collectively accounted for 91.8% of the total market share in the recent past. However, Takeda Pharmaceuticals Company Ltd clearly enjoys market dominance due to the popularity of its FDA approved drug Amitiza.
Opioids contain substances such as methadone, oxycodone, codeine, and morphine. These substances slow down central nervous system to relieve one from pain. Central nervous system is responsible for the body’s response to pain. However, central nervous system also control movements of the body, including the involuntary movements that make digestion possible. As such, usage of opioid can cause constipation.
Several drugs are available in their trial stage to treat opioid induced constipation. Many of these drugs are likely to boost the global opioid induced constipation treatment market. However, there are not enough stable choices available in the medical sector for the treatment of opioid induced constipation.
Transparency Market Research forecasts that the global opioid induced constipation treatment marketis likely to rise at a whopping 31.2% CAGRduring forecast tenure.In terms of revenue, the market is likely to reach a market value of US$4.8 billion by 2023 from US$731.2 mn over the timeframe of forecast.
Growing Usage of Illegal Medication Fuels Market
A number of factors drive the global opioid induced constipation treatment market. Growing prevalence of chronic diseases such as migraine, back pain, and arthritis, rise in incidents of opioid induced constipation amongst the elderly people are likely to offer substantial growth opportunities to developers of opioid-induced constipation treatments.
The global opioid induced constipation treatment market owes much of its growth to the expansion in the base ofillegal medication users. Additionally, procrastinated usage of opioids in chronic pain treatmentis playing an essential role inproviding impetus to the progress of the opioid induced constipation treatment market.
Increased Awareness amongst Patients and Doctors Encourage Growth
Increasedcaution amongstdoctors and patients for using non-purgative medicine options to treat opioid induced constipation is likely to promote the growth of globalopioid induced constipation treatment market. Furthermore, it has been gauged that the unexplored market for beneficial, successful, and safe medication treatment in opioid induced constipation drug is developing and is quite broad.
However, due to high costs of novel pharmaceuticals and lack ofknowledge about opioid-induced constipation and forthcoming treatment innovation among patients the market might suffer a setback.
Nevertheless, increasing rate of approval of pipeline drugs act as a beacon of hope for the global opioid induced constipation treatment market.
Large Pool of Patients with Chronic Diseases Propels North American Market
North America has always accounted for a large chunk of the global opioid induced constipation treatment market, thanks to its large consumption of opioid induced constipation treatment drugs. In terms of growth rate, North America alsooccupies the leading position. A large percentage of such patients who suffer from pain are resorting to opioids to get some relief. Ahugepart of population that takes opioid drugs also suffers from opioid induced constipation.
In addition to that, the penetration of opioid induced constipation treatments is quite low in other parts of the world as compared to North America. This likely is the reason for the high disparity of consumption rates that exists between the regions.
The information presented in this review is based on a TMR report bearingthe title,“Opioid InducedConstipation Treatment Market (Dosage–Solid, Semisolid, and Liquid; Drug Class - mu-opioid receptor antagonist, Chloride channel activator, and Others; Pipeline - Late Stage (phase III) candidates, Naldemedine, and Early Stage (phase II and phase I) candidates) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
The global opioid induced constipation treatment marketis segmented based on:
- mu-opioid receptor antagonist
- Chloride channel activator
- Late Stage (phase III) candidates
- Early Stage (phase II and phase I) candidates
- North America
- Middle East and Africa
- Asia Pacific
- Latin America
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems withright methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our Report to take the right decision.View Report